Glp-1/gdf15 dual agonist to treat obesity and hyperglycaemia in mice and non-human primates

被引：0
|
作者：
Zhang, Y. Y. [1 ]
Kharitonenkov, A. [1 ]
Zhao, X. Y. [1 ]
Dong, X. N. [1 ]
Zhang, Y. Y. [1 ]
Zou, H. X. [1 ]
Jin, Y. G. [1 ]
Guo, W. [1 ]
Zhai, P. [1 ]
Chen, X. [1 ]
机构：
[1] Beijing QL Biopharmaceut Co Ltd, Beijing, Peoples R China
来源：
DIABETOLOGIA | 2022年 / 65卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
198
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [41] Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARα/γ agonist on glycaemic control in Zucker diabetic fatty rats
    Brand, C. L.
    Galsgaard, E. D.
    Tornehave, D.
    Romer, J.
    Gotfredsen, C. F.
    Wassermann, K.
    Knudsen, L. B.
    Volund, A.
    Sturis, J.
    DIABETES OBESITY & METABOLISM, 2009, 11 (08): : 795 - 803
  • [42] MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Shows Differential Brain Activation vs. Liraglutide in Mice
    Burke, Luke K.
    Brown, Lee
    Lapointe, Jean-Martin
    Sulikowski, Michal Grzegorz
    Lewis, Arthur R.
    Trevaskis, James
    Baker, David
    DIABETES, 2018, 67
  • [43] A Novel GLP-1/FGF21 Dual Agonist ZT003 Has Therapeutic Potential for Obesity, Diabetes, and Nonalcoholic Steatohepatitis
    Zhang, Yuanyuan
    Zhang, Yuying
    Zhao, Chunlai
    Lin, Simei
    Guo, Wei
    Wu, Bo
    DIABETES, 2024, 73
  • [44] Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
    Nestor, John J.
    Parkes, David
    Feigh, Michael
    Suschak, John
    Harris, M. Scott
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [45] Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
    John J. Nestor
    David Parkes
    Michael Feigh
    John J. Suschak
    M. Scott Harris
    Scientific Reports, 12
  • [46] A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice
    Bianchini, Gianluca
    Nigro, Cecilia
    Sirico, Anna
    Novelli, Rubina
    Prevenzano, Immacolata
    Miele, Claudia
    Beguinot, Francesco
    Aramini, Andrea
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 139
  • [47] First-in-Human Single and Multiple Dose Study of the Dual GLP-1/GIP Agonist VK2735 in Healthy Adults
    Lian, Brian
    Mancini, Marianne
    Ji, Summer
    Barker, Geoff
    Neutel, Joel
    Rowland, Angela
    Bell, Francesca
    Rooney, Carmela
    Steele, Becky
    OBESITY, 2023, 31 : 41 - 42
  • [48] Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice
    Hu, Weiting
    Gong, Wenyu
    Yang, Fan
    Cheng, Rui
    Zhang, Gerong
    Gan, Lu
    Zhu, Yikun
    Qin, Weiwei
    Gao, Ying
    Li, Xing
    Liu, Jing
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 147
  • [49] Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent
    Liu, Chunxia
    Li, Chengye
    Cai, Xingguang
    Zou, Yuxing
    Mo, Jiaxian
    Chen, Bin
    Cai, Yan
    Han, Ting
    Huang, Wenlong
    Qian, Hai
    Zhang, Wenjie
    BIOORGANIC CHEMISTRY, 2021, 106
  • [50] Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
    Mahapatra, Manoj K.
    Karuppasamy, Muthukumar
    Sahoo, Biswa M.
    PHARMACEUTICAL RESEARCH, 2022, 39 (06) : 1233 - 1248
12345